Telix is turning PSMA imaging cash flows into a vertically integrated theranostic ecosystem—with blockbuster upside if FDA/CMS and legal clouds clear.
Overview
Telix has evolved from an R&D biotech into a commercial radiopharmaceutical company with a scaled U.S.-led diagnostics franchise and an emerging global footprint (launched in 21 countries). Its “See It. Treat It.” theranostic model pairs diagnostic imaging agents with targeted radiotherapies using the same tumor targets, aiming to personalize care while building a repeatable commercial pathway from scan to treatment. Illuccix anchors recurring, high-margin PSMA imaging revenue in prostate cancer, complemented by Gozellix’s late-2025 U.S. launch and reimbursement tailwind. Telix has differentiated itself through vertical integration—RLS radiopharmacies for last-mile distribution and ARTMS-enabled isotope production—which reduces supply-chain fragility versus peers. Financially, FY2025 revenue reached ~US$804M (+56% YoY) and FY2026 guidance is ~US$950–970M; group net income remains pressured by heavy R&D and integration, but core segments are cash generative. The bull case hinges on FDA approvals (Pixclara and Zircaix) and successful therapeutic trial outcomes (notably TLX591), while the main overhangs are regulatory execution, ongoing SEC/class-action risk, and pricing pressure as PSMA imaging matures.